Corcept To Test Sluggish IPO Market For Biotechs
Executive Summary
Corcept Therapeutics will test the sluggish market for biopharmaceutical initial public offerings with an IPO slated for June 10
You may also be interested in...
ZymoGenetics/Serono Will Start Lupus Trials For TACI-Ig In 2nd Half Of 2003
ZymoGenetics will initiate clinical studies for its autoimmune disease agent TACI-Ig in systemic lupus erythematosis during the second half of 2003, the company said during its Dec. 3 analyst presentation in New York
ZymoGenetics/Serono Will Start Lupus Trials For TACI-Ig In 2nd Half Of 2003
ZymoGenetics will initiate clinical studies for its autoimmune disease agent TACI-Ig in systemic lupus erythematosis during the second half of 2003, the company said during its Dec. 3 analyst presentation in New York
Danco Mifeprex Patent Extension Will Be Revised After Corcept Objects
The patent life of Danco Labs/The Population Council's Mifeprex (mifepristone, RU-486) will be shortened following a determination by FDA that the abortifacient IND became "effective" in 1983 rather than 1994